Xerophthalmia Treatment Market 2025: Industry Developments, Future Growth, Share & Industry Insights | Allergan Plc, Akorn, Inc, Thea Pharmaceuticals Limited, OASIS Medical, Scope Ophthalmics

Xerophthalmia Treatment Market is expected to grow at a CAGR of 6.2% during the forecast period 2024-2031

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/xerophthalmia-treatment-market?sg

Industry Recent Developments 2025:

✅ [2025-05-28] U.S. FDA approval and planned U.S. launch of Alcon's new prescription dry-eye drug Tryptyr a treatment that stimulates corneal sensory nerves to increase natural tear production; this class of prescription tear-stimulation therapies expands therapeutic options for severe dry-eye presentations that overlap clinically with symptomatic xerophthalmia.

✅ [2025-02-24] Alcon announced the U.S. launch of SYSTANE PRO (preservative-free) a longer-lasting artificial-tear formulation positioned for symptomatic relief of dry eye and ocular surface disease; innovations in long-duration lubricants are directly relevant to supportive care of xerophthalmia.

✅ [2025 (product trend observations)] 2025 product launches and listings showed two clear commercial trends relevant to xerophthalmia supportive care: (1) longer-lasting, preservative-free artificial tears (improved dwell time), and (2) mechanism-based prescription drops that stimulate tear production or modulate ocular surface inflammation both trends raise the standard of supportive symptom control while systemic vitamin-A therapy addresses the root cause.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/xerophthalmia-treatment-market?sg

Market growth drivers:

✅ Persistent burden of vitamin A deficiency in low- and middle-income regions - sustained endemic VAD creates continuous demand for supplementation programs and basic ocular care. (VAD prevalence remains high in many parts of Africa and South / Southeast Asia).

✅ Broader growth of the nutritional-supplement and vitamin markets - rising global awareness, distribution campaigns and commercial supplement uptake expand the overall addressable market for vitamin A products and related therapeutic packaging.

✅ Overlap with the larger dry-eye / ocular surface disease market - many xerophthalmia patients receive artificial tears and other OSD (ocular surface disease) prescriptions; growth and innovation in dry-eye therapeutics (artificial tears, in-office procedures, Rx drugs) indirectly lift the xerophthalmia treatment market's revenue potential.

✅ Public health & NGO programs - donor/NGO vaccination and supplementation campaigns (school programs,Child Health Days) sustain procurement of vitamin A and create stable institutional demand channels.

✅ Clinical/treatment improvements for severe cases - renewed interest in topical retinoids and corneal healing protocols improves outcomes and supports clinical adoption when ocular lesions occur.

Regional share & dynamics:

➠ Asia-Pacific (largest commercial and disease-burden footprint): South and Southeast Asia account for a very large share of global VAD/xerophthalmia cases and therefore represent the biggest market opportunity for both supplementation programs and growing clinical care services. Many studies estimate South/Southeast Asia supply a major portion of global cases. Commercial market growth is concentrated here because of scale and rising healthcare access.

➠ Sub-Saharan Africa (very high disease burden; constrained commercial revenue): Africa has high xerophthalmia incidence and major public-health activity; however, per-capita commercial spend on advanced ophthalmic products is smaller vs. Asia and high-income markets, so the revenue mix differs (program procurement > retail ophthalmic sales).

➠ North America & Europe (small share of disease burden, but high value per patient): True xerophthalmia from nutritional deficiency is rare; market revenue here comes from private ophthalmic care (lubricants, specialty topical agents) and treatment of secondary causes of ocular surface disease. These regions contribute disproportionately to per-unit revenue and product innovation.

Segments Covered in the Xerophthalmia Treatment Market:

By Type (Artificial Tears, Cyclosporin, Oral Corticosteroids, Punctal Plugs, Omega Supplements, Others)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other)

Regional Analysis for Xerophthalmia Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=xerophthalmia-treatment-market?sg

Major Key Players: Allergan Plc, Akorn, Inc, Thea Pharmaceuticals Limited, OASIS Medical, Scope Ophthalmics Ltd., Medicom Healthcare Ltd, FDC Limited, Jamjoom Pharmaceuticals Co., Sentiss Pharma Private Limited, Johnson & Johnson Inc.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription?sg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.